First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve

被引:153
作者
Rodriguez-Grunert, Leonardo [1 ]
Neto, Manoel Passos Galvao [2 ]
Alamo, Munir [1 ]
Ramos, Almino Cardoso [2 ]
Baez, Percy Brante [1 ]
Tarnoff, Michael [3 ]
机构
[1] Hosp Dipreca, Ctr Cirugia Obesidad, Santiago, Chile
[2] Gastro Obeso Ctr, Sao Paulo, Brazil
[3] Tufts Univ New England Med Ctr, Dept Surg, Boston, MA USA
关键词
Bariatric; Endoluminal; Diabetes; Obesity; Duodenum;
D O I
10.1016/j.soard.2007.07.012
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: We report the first human experience with an endoscopic duodenal-jejunal bypass sleeve (DJBS) in a community hospital. Methods: The DJBS is a 60-cm sleeve anchored in the duodenum to create a duodenal-jejunal bypass. In a 12-patient prospective, open-label, single-center, 12-week study, the device was endoscopically implanted, left in situ, and retrieved. The study included 5 men and 7 women, with a mean body mass index of 43 kg/m(2). Of the 12 patients, 4 had type 2 diabetes. The primary endpoints were the incidence and severity of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in co-morbid status. Results: The DJBS was endoscopically delivered and retrieved in all patients (mean implant/explant time of 26.6 and 43.3 min, respectively). Of the 12 patients, 10 were able to maintain the device for 12 weeks and 2 underwent explantation after 9 days secondary to poor device placement. Several self-limited adverse events were possibly or definitely related to the device, including 6 episodes of abdominal pain, 18 of nausea, and 16 of vomiting, mainly within 2 weeks of implantation. Two partial pharyngeal tears occurred during explantation. Implant site inflammation was encountered in all patients. No device-related event was considered severe. The average percentage of excess weight loss for the 10 patients with the device in place for 12 weeks was 23.6%, with all patients achieving at least 10% excess weight loss. All 4 diabetic patients had normal fasting plasma glucose levels without hypoglycemic medication for the entire 12 weeks. Of these 4 patients, 3 had decreased hemoglobin A(1C) of >=.5% by week 12. Conclusion: The DJBS can be safely delivered and removed endoscopically and left in situ for 12 weeks. The device had a favorable safety and encouraging efficacy profile. Randomized prospective trials are warranted. (Surg Obes Relat Dis 2008;4:55-59.) (C) 2008 American Society for Metabolic and Bariatric Surgery. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 6 条
[1]  
AULT A, 2004, 2 STAGE GASTRIC SURG
[2]  
de Paula Aureo L, 2006, Surg Obes Relat Dis, V2, P464, DOI 10.1016/j.soard.2006.03.005
[3]  
GERSIN K, 2007, APR 22 2007 SAG ANN
[4]  
*NIH, 2007, CLIN GUID ID EV TREA
[5]   Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model [J].
Patriti, A ;
Facchiano, E ;
Annetti, C ;
Aisa, MC ;
Galli, F ;
Fanelli, C ;
Donini, A .
OBESITY SURGERY, 2005, 15 (09) :1258-1264
[6]   The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes [J].
Rubino, Francesco ;
Forgione, Antonello ;
Cummings, David E. ;
Vix, Michel ;
Gnuli, Donatella ;
Mingrone, Geltrude ;
Castagneto, Marco ;
Marescaux, Jacques .
ANNALS OF SURGERY, 2006, 244 (05) :741-749